Engineered immune cells target deadly brain tumors in children
NCT ID NCT07680439
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests a new treatment called BCB-276 for children and young adults with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. BCB-276 is made from a patient's own immune cells, which are modified in a lab to recognize and attack the cancer. The treatment is given directly into the fluid around the brain every two weeks for about 7-8 months. The goal is to see if it is safe and can help people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCB-276 (a CAR T cell therapy made from the patient's own immune cells, targeting B7-H3)
What this could lead to
If successful, this could offer a new treatment option for DIPG, a rare and aggressive brain tumor with few effective therapies, potentially improving survival.
What could go wrong
This is an early-phase trial with a small number of participants. The therapy may cause serious side effects, and it is not yet known if it will improve survival compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- MR Fingerprinting for Glioblastoma Surgery (NCT06455189)
- Temozolomide (Amitzo) for Glioma Safety Study NCT07675070
- Acupuncture for Chemo Diarrhea in Kids (NCT05507736)
- Cognitive Outcomes After Brain-Sparing Radiation NCT05658731
- Brain Speech Study: How We Understand Words (NCT05435859)
- Immiseal Dural Sealant Study for Neurosurgery NCT07651826
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30329, United States
Contact Email: •••••@•••••
Contact
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Lurie Children's Hospital
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact